Propanc Biopharma, Inc. (PPCBD) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Propanc Biopharma, Inc. (PPCBD) trades at $5.68. Propanc Biopharma, Inc. is a biopharmaceutical company focused on developing cancer treatments, particularly for pancreatic, ovarian, and colorectal cancers. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for PPCBD: PPCBD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PPCBD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on PPCBD.
How is this calculated? →Propanc Biopharma, Inc. (PPCBD) Healthcare & Pipeline Overview
Propanc Biopharma, Inc. is an Australian biopharmaceutical firm specializing in preclinical cancer therapeutics, primarily PRP, targeting pancreatic, ovarian, and colorectal cancers. The company collaborates with universities for drug discovery programs, operating in a competitive biotechnology landscape with a focus on novel enzyme-based treatments.
What Is the Investment Thesis for PPCBD?
Propanc Biopharma, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value hinges on the successful development and eventual commercialization of its lead product, PRP. Currently in the preclinical phase, PRP's potential to enhance the anti-cancer effects of multiple enzymes represents a significant value driver. However, the company's extremely negative profit margin of -220932.3% and small market capitalization of $0.00B highlight the speculative nature of this investment. Growth catalysts include advancing PRP through clinical trials and securing partnerships for further development and commercialization. The company's research collaborations with universities could also yield valuable insights and accelerate drug discovery. Key risks include the inherent uncertainty of drug development, the need for substantial additional funding, and the competitive landscape of the biotechnology industry. Investors should carefully consider the company's financial position and the long-term nature of pharmaceutical development.
Based on FMP financials and quantitative analysis
PPCBD Key Highlights
Propanc Biopharma, Inc. is focused on developing cancer treatments for pancreatic, ovarian, and colorectal cancer.
- The company's lead product, PRP, is in the preclinical phase and designed to enhance the anti-cancer effects of multiple enzymes.
- Propanc Biopharma has a research collaboration with the University of Jaén for the POP1 joint drug discovery program.
- The company has a joint research program with the Universities of Jaén and Granada to investigate genetic and protein expression changes in cancer cells.
- Propanc Biopharma's market capitalization is $0.00B, reflecting its early-stage development and speculative investment profile.
Who Are PPCBD's Competitors?
PPCBD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PPCBD's Key Strengths?
Focus on developing treatments for cancers with high unmet needs.
- Proprietary formulation (PRP) in preclinical development.
- Research collaborations with universities.
- Small size allows for agility and focus.
What Are PPCBD's Weaknesses?
Limited financial resources and reliance on external funding.
- Early-stage development with no products currently on the market.
- Small team with limited operational capacity.
- High dependence on the success of PRP.
What Could Drive PPCBD Stock Higher?
Announcement of preclinical study results for PRP.
- Potential partnership with a pharmaceutical company.
- Research and development progress in collaboration with universities.
- Efforts to secure additional funding through grants or equity offerings.
- Initiation of Phase 1 clinical trials for PRP (timeline dependent on funding).
What Are the Key Risks for PPCBD?
Financial-distress signal — its Altman Z-Score of -18.59 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Failure to secure additional funding for continued development.
- Unsuccessful clinical trials for PRP.
- Competition from larger pharmaceutical companies with established oncology portfolios.
- Changes in regulatory requirements or healthcare policies.
- Delays in research and development timelines.
What Are the Growth Opportunities for PPCBD?
- Advancement of PRP through Clinical Trials: Propanc Biopharma's primary growth opportunity lies in advancing its lead product, PRP, through the clinical trial process. Successful completion of preclinical studies and subsequent Phase 1, 2, and 3 trials could significantly increase the company's value. The timeline for this growth opportunity depends on regulatory approvals and funding availability, but represents a potentially transformative event for the company.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions represents another key growth opportunity for Propanc Biopharma. These partnerships could provide access to additional funding, expertise, and resources necessary to accelerate the development and commercialization of PRP. The biotechnology industry is characterized by collaborations and acquisitions, and Propanc Biopharma could benefit from aligning with a larger player. The timing of these partnerships is uncertain but could materialize within the next few years.
- Expansion of the Drug Pipeline: Propanc Biopharma could expand its drug pipeline by developing additional cancer therapeutics beyond PRP. This could involve targeting different types of cancer or exploring alternative mechanisms of action. A broader pipeline would diversify the company's risk and increase its potential for long-term growth. The timeline for this growth opportunity depends on the company's research and development capabilities and funding availability, but could unfold over the next several years.
- Exploitation of POP1 Joint Drug Discovery Program: The research collaboration with the University of Jaén for the POP1 joint drug discovery program presents a growth opportunity for Propanc Biopharma. This program could lead to the identification of novel drug targets and the development of new cancer therapeutics. The success of this program depends on the outcomes of the research activities and the ability to translate findings into viable drug candidates. The timeline for this growth opportunity is uncertain but could yield results within the next few years.
- Geographic Expansion: While currently focused on the Australian market, Propanc Biopharma could expand its geographic reach by seeking regulatory approvals and commercializing its products in other countries. The global market for cancer therapeutics is vast, and expanding into new markets could significantly increase the company's revenue potential. The timeline for this growth opportunity depends on regulatory approvals and market entry strategies, but could unfold over the next several years.
What Are PPCBD's Competitive Advantages?
- Proprietary formulations and intellectual property related to PRP.
- Research collaborations with leading universities.
- Focus on specific cancer types with unmet medical needs.
What Does PPCBD Do?
Propanc Biopharma, Inc., established in 2007 and based in Camberwell, Australia, is a biopharmaceutical company dedicated to the development of novel cancer treatments. The company focuses on addressing unmet medical needs in pancreatic, ovarian, and colorectal cancers. Its lead product, PRP, is a formulation currently in the preclinical phase, designed to enhance the anti-cancer effects of multiple enzymes. PRP represents the core of Propanc's therapeutic strategy, aiming to improve outcomes for patients with these challenging cancers. Propanc Biopharma actively engages in research collaborations to advance its drug discovery efforts. A notable collaboration is with the University of Jaén, focusing on the POP1 joint drug discovery program. Additionally, the company has a joint research and drug discovery program with the Universities of Jaén and Granada, investigating genetic and protein expression changes in cancer cells. These collaborations underscore Propanc's commitment to innovative research and development in the field of oncology. Formerly known as Propanc Health Group Corporation, the company rebranded as Propanc Biopharma, Inc. in April 2017, reflecting its sharpened focus on biopharmaceutical research and development.
What Products and Services Does PPCBD Offer?
- Develop cancer treatments for pancreatic cancer.
- Develop cancer treatments for ovarian cancer.
- Develop cancer treatments for colorectal cancer.
- Focus on enhancing the anti-cancer effects of multiple enzymes.
- Engage in research collaborations with universities.
- Conduct preclinical studies for its lead product, PRP.
- Investigate genetic and protein expression changes in cancer cells.
How Does PPCBD Make Money?
- Develops and patents novel cancer therapeutics.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Secures funding through grants, equity offerings, and partnerships.
What Industry Does PPCBD Operate In?
Propanc Biopharma operates within the highly competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and a high degree of risk. The company focuses on cancer therapeutics, a market driven by the increasing global incidence of cancer and the demand for more effective treatments. The biotechnology industry is experiencing growth, fueled by technological advancements in genomics, proteomics, and personalized medicine. Propanc Biopharma's success depends on its ability to navigate the complex regulatory landscape, secure funding, and differentiate its products from those of larger, more established competitors.
Who Are PPCBD's Key Customers?
- Ultimately, cancer patients suffering from pancreatic, ovarian, and colorectal cancers.
- Pharmaceutical companies seeking to expand their oncology portfolios.
- Healthcare providers and institutions.
Company Profile
Propanc Biopharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Camberwell, AU. The company is led by CEO James Nathanielsz. PPCBD has traded publicly since 2012.
Financial Health
Propanc Biopharma, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -18.59 places it in the distress zone, a signal of elevated financial risk.
PPCBD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Focus on developing treatments for cancers with high unmet needs.
- Proprietary formulation (PRP) in preclinical development.
- Research collaborations with universities.
- Small size allows for agility and focus.
Bear Case
- Limited financial resources and reliance on external funding.
- Early-stage development with no products currently on the market.
- Small team with limited operational capacity.
- High dependence on the success of PRP.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
PPCBD Latest News
No recent news available for PPCBD.
PPCBD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PPCBD.
Price Targets
Wall Street price target analysis for PPCBD.
PPCBD MoonshotScore
What does this score mean?
The MoonshotScore rates PPCBD 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: James Nathanielsz
Managing Director
James Nathanielsz serves as the Managing Director of Propanc Biopharma, Inc. His background includes experience in managing small teams and guiding early-stage companies. He has been involved in the strategic direction and operational oversight of Propanc Biopharma, focusing on advancing the company's research and development programs. His expertise lies in navigating the challenges of the biotechnology industry and securing funding for research initiatives. He manages a team of 1 employee.
Track Record: Under James Nathanielsz's leadership, Propanc Biopharma has focused on advancing its lead product, PRP, through the preclinical phase. He has overseen the company's research collaborations with universities and has been instrumental in securing funding for research activities. His tenure has been marked by a focus on strategic partnerships and the development of the company's intellectual property portfolio.
PPCBD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, characterized by limited listing requirements and minimal financial disclosure standards compared to exchanges like the NYSE or NASDAQ. Companies in this tier may not meet the minimum financial or operational standards required for listing on higher-tier exchanges. This tier often includes companies with limited operating history, distressed financials, or those that choose not to comply with stricter reporting requirements. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or bankruptcy.
- Lack of regulatory oversight.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements (if available).
- Assess the company's management team and track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's funding sources and cash flow.
- Monitor news and announcements related to the company.
- Consult with a financial advisor before investing.
- Company has a registered business address.
- Company has a functional website with contact information.
- Company has a management team listed.
- Company engages in research collaborations with reputable universities.
- Company has a patent portfolio (PRP).
Propanc Biopharma, Inc. Healthcare Stock: Key Questions Answered
What does Propanc Biopharma, Inc. do?
Propanc Biopharma, Inc. is a biopharmaceutical company focused on developing novel cancer treatments, primarily targeting pancreatic, ovarian, and colorectal cancers. Their lead product, PRP, is a formulation in the preclinical phase designed to enhance the anti-cancer effects of multiple enzymes. The company collaborates with universities for research and development, aiming to address unmet medical needs in the oncology space.
What do analysts say about PPCBD stock?
As a micro-cap OTC stock with limited analyst coverage, there is no established analyst consensus for Propanc Biopharma, Inc. (PPCBD). Key valuation metrics are difficult to assess due to the company's early-stage development and lack of revenue. Growth considerations center on the successful advancement of PRP through clinical trials and the potential for strategic partnerships.
What are the main risks for PPCBD?
Propanc Biopharma, Inc. faces significant risks inherent to its early-stage development and OTC listing. These include the risk of failure in clinical trials for PRP, the need for substantial additional funding, competition from larger pharmaceutical companies, and the potential for regulatory setbacks.
What are the key factors to evaluate for PPCBD?
Evaluate PPCBD on fundamentals, analyst consensus, and risk factors. Propanc Biopharma, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does PPCBD data refresh on this page?
PPCBD's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PPCBD's recent stock price performance?
Propanc Biopharma, Inc. (PPCBD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on developing treatments for cancers with high unmet needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PPCBD overvalued or undervalued right now?
Propanc Biopharma, Inc. (PPCBD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PPCBD before investing?
Before investing in Propanc Biopharma, Inc. (PPCBD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be limited due to the company's OTC listing and limited financial disclosure.
- The biotechnology industry is inherently risky, and investment decisions should be made with caution.